Cobalt Protoporphyrin (CoPP) has been shown to have considerable pharmacological benefit in models of diabetes-linked vascular and renal damage [42]–[45], Ang II mediated hypertension [46], [47], renovascular hypertension [48], arterial thrombosis [49] and other oxidative stress-mediated pathologies. This evidence concerns the gene AGT and renovascular hypertension.